Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Swedish Orphan Biovitrum    SOBI   SE0000872095

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
01/16/2018 01/17/2018 01/18/2018 01/19/2018 01/22/2018 Date
117.45(c) 117.05(c) 115.8(c) 116.5(c) 135.7 Last
662 347 877 618 557 994 784 459 6 217 591 Volume
+1.29% -0.34% -1.07% +0.60% +16.48% Change
More quotes
Financials ( SEK)
Sales 2017 6 389 M
EBIT 2017 1 529 M
Net income 2017 1 101 M
Finance 2017 1 275 M
Yield 2017 -
Sales 2018 7 876 M
EBIT 2018 2 300 M
Net income 2018 1 768 M
Finance 2018 2 253 M
Yield 2018 0,44%
P/E ratio 2017 28,56
P/E ratio 2018 17,77
EV / Sales2017 4,77x
EV / Sales2018 3,74x
Capitalization 31 747 M
More Financials
Company
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company.It provides therapies and services for patients with rare diseases.The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Surperformance© ratings of Swedish Orphan Biovitrum
Trading Rating : Investor Rating :
More Ratings
Latest news on SWEDISH ORPHAN BIOVITRUM
06:16p Dealmaking drives European stocks as equity melt-up continues
04:48p New drugs recast $10 billion haemophilia market as Sanofi swoops in
2017 SWEDISH ORPHAN BIOVITRUM AB : - New data show extended prophylactic dosing with ..
2017 SOBI : Launches Orfadin® (nitisinone) Ambassador Program to Support Patients and..
2017 BIOVERATIV : Swedish Orphan Biovitrum AB Study shows weekly prophylactic treatme..
2017 SWEDISH ORPHAN BIOVITRUM : New data show extended prophylactic dosing with Alpro..
2017 SWEDISH ORPHAN BIOVITRUM : Study shows weekly prophylactic treatment with Elocta..
2017 SWEDISH ORPHAN BIOVITRUM : Sobi receives approval from Health Canada for Orfadin..
2017 SOBI : ™ Receives Approval from Health Canada for Orfadin® (nitisinone) Or..
2017 SWEDISH ORPHAN BIOVITRUM : First patient randomised in study evaluating safety a..
More news
Sector news : Pharmaceuticals - NEC
06:16p Dealmaking drives European stocks as equity melt-up continues
06:14p UK stocks decline as gamblers stumble on government clampdown worries
05:23p Biotech M&A takes off as Sanofi and Celgene spend $20 billion
05:05p CELGENE : to Buy Juno Therapeutics for $9 Billion -- 2nd Update
04:55p Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
More sector news : Pharmaceuticals - NEC
Latest Tweets
2017Swedish Orphan Biovitrum : Norbert Oppitz Joins Sobi(TM) as New Senior Vice P.. 
2017Myocarditis - Pipeline Review, H2 2017 Featuring CEL-SCI, GlaxoSmithKline &am.. 
2017Swedish Orphan Biovitrum : FDA grants SOBI003 Orphan Drug Designation for the.. 
2017Swedish Orphan Biovitrum AB - Elocta® Approved in the Kingdom of Saudi Arabia.. 
2017Swedish Orphan Biovitrum AB : - Elocta® Approved in the Kingdom of Saudi Arab.. 
More tweets
Qtime:21
News from SeekingAlpha
2017 Bioverativ's Eloctate demonstrates positive effect on joints in hemophilia A ..
2017 Swedish Orphan Biovitrum AB ADR 2017 Q3 - Results - Earnings Call Slides
2017 BIOVERATIV : Just Stop The Bleeding
2017 Sobi inks Ammonul distribution deal with Valeant
2016 Reassessing Biogen
Chart SWEDISH ORPHAN BIOVITRUM
Duration : Period :
Swedish Orphan Biovitrum Technical Analysis Chart | SOBI | SE0000872095 | 4-Traders
Technical analysis trends SWEDISH ORPHAN BIOVITRUM
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 136  SEK
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Guido Oelkers President & Chief Executive Officer
Sven Håkan Björklund Chairman
Mats-Olof Wallin Chief Financial Officer & Senior Vice President
Marianne Keisu Chief Medical Officer & Vice President
Milan Zdravkovic Senior Vice President, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM3.74%3 940
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132